Evinacumab-dgnb: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 May 2024

  • curprev 23:4223:42, 27 May 2024 Jonathan Reyes talk contribs 627 bytes +627 Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero..."
Retrieved from "https://www.wikidoc.org/index.php/Evinacumab-dgnb"